Your browser doesn't support javascript.
loading
Cardiotoxicities of Novel Therapies in Hematologic Malignancies: Chimeric Antigen Receptor T-Cell Therapy and Bispecific T-Cell Engager Therapy.
Marar, Rosalyn I; Abbasi, Muhannad Aboud; Prathivadhi-Bhayankaram, Sruti; Daryanani, Andres; Villarraga, Hector; Anavekar, Nandan; Bhatt, Vijaya Raj; Paludo, Jonas.
Afiliação
  • Marar RI; Division of Hematology-Oncology, University of Nebraska Medical Center, Omaha, NE.
  • Abbasi MA; Division of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.
  • Prathivadhi-Bhayankaram S; Division of Internal Medicine, University of Iowa Healh Care, Iowa City, IA.
  • Daryanani A; Division of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.
  • Villarraga H; Division of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.
  • Anavekar N; Division of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.
  • Bhatt VR; Division of Hematology-Oncology, University of Nebraska Medical Center, Omaha, NE.
  • Paludo J; Division of Hematology-Oncology, Mayo Clinic, Rochester, MN.
JCO Oncol Pract ; 19(6): 331-342, 2023 06.
Article em En | MEDLINE | ID: mdl-36930845
The field of malignant hematology is transforming with novel immunotherapeutic approaches. Unfortunately, quality of life, treatment efficacy, and life expectancy are negatively affected by cardiotoxic side effects of treatment. To date, the exact mechanism and incidence of cardiotoxicity associated with these therapies is unclear. These events are believed to be triggered or occur concurrently with cytokine release syndrome. Furthermore, there are no formal guidelines to provide evaluation, treatment, and surveillance. We aim to synthesize available literature with updates on the cardiotoxic effects of novel therapies used in malignant hematologic disorders, with a focus on chimeric antigen receptor T-cell therapy and bispecific T-cell engager therapy, along with a proposed algorithm that may guide pretreatment evaluation, monitoring during treatment, and post-treatment surveillance.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Hematológicas / Receptores de Antígenos Quiméricos / Neoplasias Tipo de estudo: Guideline Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Hematológicas / Receptores de Antígenos Quiméricos / Neoplasias Tipo de estudo: Guideline Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article